Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Use of biological mesh in trans-anal treatment for recurrent recto-urethral fistula

  • 429 Accesses

Dear Editor,

I read with interest the letter by Deepak Batura about our paper entitled “Use of biological mesh in trans-anal treatment for recurrent recto-urethral fistula”. I thank the colleague for his accurate comments. I take this opportunity to clarify the following points:

  1. 1.

    All 7 patients reported in the original article underwent double diversion at least 2 months before the author’s procedure. In this situation, no enteric preparation is necessary with a surgical field clean and ideal to use a mesh in a potential infected site. The biological mesh has a great capacity to progressively integrate itself;

  2. 2.

    All 7 patients we described underwent extensive clinical investigations during serial follow-up visits that excluded urethral stricture, signs of infections or urethral sequelae. That is way the patients did not undergo extra examinations (endoscopic or bacteriological) once the stoma was closed.

I hope this additional information will help to clarify your queries.

Author information

Correspondence to Marco Inama.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Inama, M. Use of biological mesh in trans-anal treatment for recurrent recto-urethral fistula. Int Urol Nephrol 49, 2169 (2017). https://doi.org/10.1007/s11255-017-1704-x

Download citation